Inventor · disambiguated record
Michael Bristow
Also filed as: BRISTOW MICHAEL · BRISTOW MICHAEL R
20 granted patents·19 pending applications·219 citations·filing 1998–2023
94Inventor score
Files withUNIV COLORADO REGENTS8ARCA BIOPHARMA INC6UNIV COLORADO5LIGGETT STEPHEN B3UNIV TECHNOLOGY CORP3
Top patents by PatentIndex Score
39 records- 0195US6706686B2Inhibition of histone deacetylase as a treatment for cardiac hypertrophyUNIV COLORADO·Filed 2002·Granted Mar 16, 2004·92 cites·50 claims
- 0292US6946441B2Inhibition of histone deacetylase as a treatment for cardiac hypertrophyUNIV TEXAS·Filed 2004·Granted Sep 20, 2005·45 cites·10 claims
- 0391US7678824B2Methods for treatment with bucindolol based on genetic targetingUNIV COLORADO REGENTS·Filed 2005·Granted Mar 16, 2010·13 cites·16 claims
- 0488US9446023B2Methods and compositions involving (S)-bucindololARCA BIOPHARMA INC·Filed 2015·Granted Sep 20, 2016·7 cites·11 claims
- 0586US9763916B2Methods and compositions involving (S)-bucindololARCA BIOPHARMA INC·Filed 2016·Granted Sep 19, 2017·5 cites·10 claims
- 0685US8093286B2Methods for treatment with bucindolol based on genetic targetingLIGGETT STEPHEN B·Filed 2007·Granted Jan 10, 2012·5 cites·22 claims
- 0784US8946284B2Methods and compositions involving (S)-bucindololBRISTOW MICHAEL R·Filed 2009·Granted Feb 3, 2015·10 cites·21 claims
- 0876US8080578B2Methods for treatment with bucindolol based on genetic targetingLIGGETT STEPHEN B·Filed 2007·Granted Dec 20, 2011·1 cites·28 claims
- 0972US12491177B2Methods and compositions involving bucindolol for the treatment of atrial fibrillationGENVARA BIOPHARMA INC·Filed 2023·Granted Dec 9, 2025·0 cites·19 claims
- 1072US11554107B2Methods and compositions involving bucindolol for the treatment of atrial fibrillationARCA BIOPHARMA INC·Filed 2021·Granted Jan 17, 2023·0 cites·20 claims
- 1169US11452712B2Methods and compositions involving (S)-bucindololARCA BIOPHARMA INC·Filed 2018·Granted Sep 27, 2022·0 cites·8 claims
- 1269US10925856B2Methods and compositions involving bucindolol for the treatment of atrial fibrillationARCA BIOPHARMA INC·Filed 2020·Granted Feb 23, 2021·0 cites·24 claims
- 1369US7482331B1Diagnosis and treatment of myocardial failureUNIV COLORADO·Filed 2000·Granted Jan 27, 2009·1 cites·1 claims
- 1465US7049066B2Diagnosis and treatment of myocardial failureUNIV COLORADO·Filed 2001·Granted May 23, 2006·1 cites·9 claims
- 1565US5998458AMethod of treating heart failureUNIV TECHNOLOGY CORP·Filed 1998·Granted Dec 7, 1999·21 cites·15 claims
- 1665US2015276717A1Methods for treatment with bucindolol based on genetic targetingUNIV COLORADO REGENTS·Filed 2014·Application pending·0 cites
- 1762US2018156782A1Methods for Treatment with Bucindolol Based on Genetic TargetingUNIV COLORADO REGENTS·Filed 2017·Application pending·0 cites
- 1861US8916603B2Methods for treatment with bucindolol based on genetic targetingLIGGETT STEPHEN B·Filed 2011·Granted Dec 23, 2014·0 cites·5 claims
- 1959US2015141495A1Differential expression of micrornas in nonfailing versus failing human heartsUNIV COLORADO REGENTS·Filed 2014·Application pending·0 cites
- 2058US2018161309A1Methods and compositions involving (s)-bucindololARCA BIOPHARMA INC·Filed 2017·Application pending·0 cites
- 2156US2020239957A1Prediction and treatment of heart failureUNIV COLORADO REGENTS·Filed 2019·Application pending·0 cites
- 2256US2016237498A1Prediction and treatment of heart failureUNIV COLORADO REGENTS·Filed 2014·Application pending·0 cites
- 2354US2006069014A1Inhibition of histone deacetylase as a treatment for cardiac hypertrophyLONG CARLIN·Filed 2005·Application pending·0 cites
- 2454US2006025333A1Inhibition of histone deacetylase as a treatment for cardiac hypertrophyLONG CARLIN·Filed 2005·Application pending·0 cites
- 2553US2005214835A1Diagnosis and treatment of myocardial failureUNIV COLORADO·Filed 2005·Application pending·0 cites
- 2651US2010267804A1Differential expression of micrornas in nonfailing versus failing human heartsPORT JONATHAN DAVID·Filed 2008·Application pending·0 cites
- 2751US2013310436A1Methods for predicting response to beta-blocker therapy in non-ischemic heart failure patientsUNIV COLORADO REGENTS·Filed 2013·Application pending·0 cites
- 2846US2017081722A1Polymorphisms in the pde3a geneUNIV COLORADO REGENTS·Filed 2016·Application pending·0 cites
- 2944US2006018970A1Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failureAVENTIS PHARMA INC·Filed 2004·Application pending·0 cites
- 3043US9512481B2Polymorphisms in the PDE3A geneSUCHAROV CARMEN·Filed 2010·Granted Dec 6, 2016·0 cites·12 claims
- 3141US2006025463A1Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseasesBRISTOW MICHAEL·Filed 2005·Application pending·0 cites
- 3238US6218597B1Transgenic model and treatment for heart diseaseUNIV TECHNOLOGY CORP·Filed 1998·Granted Apr 17, 2001·3 cites·23 claims
- 3336US2009220507A1Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failureSUCHAROV CARMEN C·Filed 2006·Application pending·0 cites
- 3436US2013131161A1Methods and compositions for cardiovascular diseases and conditionsBRISTOW MICHAEL R·Filed 2010·Application pending·0 cites
- 3535US6167361ARacing vehicle four-link configuration method and apparatusFiled 1999·Granted Dec 26, 2000·10 cites·14 claims
- 3635US2006292213A1Enoximone formulations and their use in the treatment of PDE-III mediated diseasesMYOGEN INC·Filed 2005·Application pending·0 cites
- 3735US2006030611A1Enoximone sulfoxide enantiomers and their use in the treatment of PDE-III mediated diseasesMYOGEN INC·Filed 2005·Application pending·0 cites
- 3834US6203776B1Method for identifying adrenergic receptor antagonists having good tolerabilityUNIV TECHNOLOGY CORP·Filed 1998·Granted Mar 20, 2001·5 cites·28 claims
- 3933US2003096782A1Expression profiling in the intact human heartUNIV COLORADO·Filed 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →